Celldex Therapeutics Inc (CLDX) 20.97 $CLDX
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.03 (unch), CLDX: 20.97 (+0.53), JUNO: 40.52 (+0.18), XOMA: 3.41 (-0.01), PDLI: 7.28 (+0.03)
Celldex Therapeutics Announces Upcoming Presentation at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 7:06AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Executive Vice President and Chief Medical Officer, are scheduled to present a corporate overview at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 10:20 am ET at the Waldorf Astoria in New York City.
CLDX: 20.97 (+0.53)
CDX-011 Shows Promise in Advanced Breast Cancer Ailment
M2 - Sat Jan 31, 12:16AM CST
According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", CDX-011 is a fully human monoclonal antibody drug conjugate targeting glycoprotein non-metastatic b (GPNMB) protein. GPNMB is expressed by multiple tumor types including breast cancer and melanoma. This antibody candidate is linked to potent cytotoxic monomethyl auristatin E using Seattle's genetic proprietary technology. In 2013, Celldex Therapeutics launched a METRIC study of CDX-011 in patients with metastatic triple negative breast cancer with over expressed glycoprotein NMB. The aim of the study was to investigate the safety of CDX-011 in patients having advanced triple negative breast cancer in Phase II. The study was successful in overcoming breast cancer.
CLDX: 20.97 (+0.53)
Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 4:25PM CST
Celldex Therapeutics (CLDX) and Bristol-Myers Squibb Company (BMY) announced the commencement of a phase I/II dose escalation and cohort expansion study to evaluate Celldex's varlilumab in combination with Bristol-Myers' Opdivo in patients with advanced refractory solid tumor.
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors
GlobeNewswire - Thu Jan 29, 7:00AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational immune-activating antibody and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab). The study will be conducted in adult patients with advanced non-small cell lung cancer (NSCLC), metastatic melanoma (MEL), colorectal cancer (CRC), ovarian cancer, and head and neck squamous cell carcinoma (SCCHN). Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor expressed on activated T-cells. This study will evaluate the safety and tolerability of the combination and address the hypothesis that the combination of these two mechanisms enhance the anti-tumor activity compared to either agent alone. Celldex is responsible for conducting the study and development costs will be shared.
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Undervalued Celldex Offers Upside Opportunity
Kanak Kanti De - at Seeking Alpha - Wed Jan 21, 1:14PM CST
CLDX: 20.97 (+0.53)
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock
at The Street - Wed Jan 21, 9:25AM CST
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CLDX: 20.97 (+0.53)
Celldex Therapeutics (CLDX) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 7:51AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose almost 9% on the day.
CLDX: 20.97 (+0.53), AMAG: 41.49 (+0.23)
Watch for Celldex Therapeutics to Potentially Pullback After Gaining 8.91% Yesterday
Comtex SmarTrend(R) - Fri Jan 16, 4:05PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $18.48 to a high of $20.43. Yesterday, the shares gained 8.9%, which took the trading range above the 3-day high of $19.41 on volume of 13.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 20.97 (+0.53)
Celldex Therapeutics Still Building Its Immuno-Oncology Story
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:40PM CST
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.96 (-0.03), BLCM: 20.00 (-0.81), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), CLDX: 20.97 (+0.53), CALA: 16.11 (+0.62), AGIO: 118.55 (+0.11)
Traders Are Placing Long-Term Bets on Celldex Therapeutics
at The Street - Tue Jan 06, 4:45AM CST
Traders place long-term bets on Celldex Therapeutics, bucking the broad market downturn.
CLDX: 20.97 (+0.53)
Is Northwest Biotherapeutics A Bargain? Yes!
Ryan Pawell - at Seeking Alpha - Sun Jan 04, 11:17PM CST
NWBO: 6.07 (+0.13), CLDX: 20.97 (+0.53)
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma
PR Newswire - Wed Dec 31, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics Inc. (NASDAQ: CLDX), Juno Therapeutics Inc. (NASDAQ: JUNO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 30, 2014, the NASDAQ Composite ended at 4,777.44, down 0.61%, the Dow Jones Industrial Average lost 0.31%, to finish the day at 17,983.07, and the S&P 500 closed at 2,080.35, down 0.49%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.80, down 0.41%, while the index has advanced 8.09% in the previous three months. Register for your complimentary reports on these five stocks at:
IRWD: 15.15 (-0.85), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), JUNO: 40.52 (+0.18), MNKD: 7.00 (+0.02)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
After Yesterday's Decline of 1.04%, Celldex Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Dec 24, 4:31PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $16.96 to a high of $17.66. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $17.13 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLDX: 20.97 (+0.53)
4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST
JNJ: 99.62 (+1.18), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), CLDX: 20.97 (+0.53)
Six Biotech and Technology Stocks With Strong Technical Set-Ups
at The Street - Thu Dec 18, 12:44PM CST
Wednesday's session featured some good moves and technical set-ups, particularly in biotech and technology.
RDUS: 50.37 (+0.63), OREX: 5.55 (+0.10), ACHN: 10.89 (-0.20), CLDX: 20.97 (+0.53), TASR: 26.96 (-0.42), DATA: 99.90 (+1.40)
Celldex Therapeutics Announces Appointment to Board of Directors
GlobeNewswire - Thu Dec 18, 7:10AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the appointment of Richard A. van den Broek to the Company's Board of Directors. Mr. van den Broek currently serves as a Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry. In addition, the Company announced that Timothy Shannon, MD has resigned from the Board due to demands on his time, including his roles as Chairman of the Board of Directors of Arvinas, Inc., a privately held biotechnology company and as a General Partner at Canaan Partners.
CLDX: 20.97 (+0.53)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.03 (unch), CLDX: 20.97 (+0.53), JUNO: 40.52 (+0.18), XOMA: 3.41 (-0.01), PDLI: 7.28 (+0.03)
Celldex Therapeutics Announces Upcoming Presentation at the 2015 Leerink Global Healthcare Conference
GlobeNewswire - Mon Feb 09, 7:06AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Executive Vice President and Chief Medical Officer, are scheduled to present a corporate overview at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 10:20 am ET at the Waldorf Astoria in New York City.
CLDX: 20.97 (+0.53)
CDX-011 Shows Promise in Advanced Breast Cancer Ailment
M2 - Sat Jan 31, 12:16AM CST
According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", CDX-011 is a fully human monoclonal antibody drug conjugate targeting glycoprotein non-metastatic b (GPNMB) protein. GPNMB is expressed by multiple tumor types including breast cancer and melanoma. This antibody candidate is linked to potent cytotoxic monomethyl auristatin E using Seattle's genetic proprietary technology. In 2013, Celldex Therapeutics launched a METRIC study of CDX-011 in patients with metastatic triple negative breast cancer with over expressed glycoprotein NMB. The aim of the study was to investigate the safety of CDX-011 in patients having advanced triple negative breast cancer in Phase II. The study was successful in overcoming breast cancer.
CLDX: 20.97 (+0.53)
Celldex/Bristol-Myers Initiate Phase I/II Solid Tumor Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 4:25PM CST
Celldex Therapeutics (CLDX) and Bristol-Myers Squibb Company (BMY) announced the commencement of a phase I/II dose escalation and cohort expansion study to evaluate Celldex's varlilumab in combination with Bristol-Myers' Opdivo in patients with advanced refractory solid tumor.
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02), CELG: 115.88 (+0.16)
Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors
GlobeNewswire - Thu Jan 29, 7:00AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational immune-activating antibody and Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab). The study will be conducted in adult patients with advanced non-small cell lung cancer (NSCLC), metastatic melanoma (MEL), colorectal cancer (CRC), ovarian cancer, and head and neck squamous cell carcinoma (SCCHN). Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor expressed on activated T-cells. This study will evaluate the safety and tolerability of the combination and address the hypothesis that the combination of these two mechanisms enhance the anti-tumor activity compared to either agent alone. Celldex is responsible for conducting the study and development costs will be shared.
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Undervalued Celldex Offers Upside Opportunity
Kanak Kanti De - at Seeking Alpha - Wed Jan 21, 1:14PM CST
CLDX: 20.97 (+0.53)
Trade-Ideas: Celldex Therapeutics (CLDX) Is Today's "Barbarian At The Gate" Stock
at The Street - Wed Jan 21, 9:25AM CST
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CLDX: 20.97 (+0.53)
Celldex Therapeutics (CLDX) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 7:51AM CST
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose almost 9% on the day.
CLDX: 20.97 (+0.53), AMAG: 41.49 (+0.23)
Watch for Celldex Therapeutics to Potentially Pullback After Gaining 8.91% Yesterday
Comtex SmarTrend(R) - Fri Jan 16, 4:05PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $18.48 to a high of $20.43. Yesterday, the shares gained 8.9%, which took the trading range above the 3-day high of $19.41 on volume of 13.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 20.97 (+0.53)
Celldex Therapeutics Still Building Its Immuno-Oncology Story
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 14, 4:40PM CST
CLDX: 20.97 (+0.53), BMY: 60.04 (+0.56)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.96 (-0.03), BLCM: 20.00 (-0.81), GILD: 101.90 (+1.10), KITE: 62.59 (+0.82), CLDX: 20.97 (+0.53), CALA: 16.11 (+0.62), AGIO: 118.55 (+0.11)
Traders Are Placing Long-Term Bets on Celldex Therapeutics
at The Street - Tue Jan 06, 4:45AM CST
Traders place long-term bets on Celldex Therapeutics, bucking the broad market downturn.
CLDX: 20.97 (+0.53)
Is Northwest Biotherapeutics A Bargain? Yes!
Ryan Pawell - at Seeking Alpha - Sun Jan 04, 11:17PM CST
NWBO: 6.07 (+0.13), CLDX: 20.97 (+0.53)
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma
PR Newswire - Wed Dec 31, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics Inc. (NASDAQ: CLDX), Juno Therapeutics Inc. (NASDAQ: JUNO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 30, 2014, the NASDAQ Composite ended at 4,777.44, down 0.61%, the Dow Jones Industrial Average lost 0.31%, to finish the day at 17,983.07, and the S&P 500 closed at 2,080.35, down 0.49%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.80, down 0.41%, while the index has advanced 8.09% in the previous three months. Register for your complimentary reports on these five stocks at:
IRWD: 15.15 (-0.85), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), JUNO: 40.52 (+0.18), MNKD: 7.00 (+0.02)
Will Biotech Fire On All Cylinders In 2015?
Life Sciences Report - at Seeking Alpha - Tue Dec 30, 3:15PM CST
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early...
MDT: 75.26 (+0.33), PFE: 34.64 (-0.23), CLDX: 20.97 (+0.53), COV: 106.71 (-1.36), INCY: 75.94 (+0.28), NBS: 3.78 (+0.14), BMY: 60.04 (+0.56), OMER: 20.63 (+0.13), CELG: 115.88 (+0.16), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), NVAX: 8.80 (+0.40), AZN: 69.96 (+0.20), CEMP: 27.68 (+1.25), FPRX: 24.63 (+0.63)
After Yesterday's Decline of 1.04%, Celldex Therapeutics Offers Investors Better Value
Comtex SmarTrend(R) - Wed Dec 24, 4:31PM CST
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $16.96 to a high of $17.66. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $17.13 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLDX: 20.97 (+0.53)
4 Reasons I'm Adding Gilead To My Healthcare Holdings
Brian Nichols - at Seeking Alpha - Wed Dec 24, 6:18AM CST
JNJ: 99.62 (+1.18), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), CLDX: 20.97 (+0.53)
Six Biotech and Technology Stocks With Strong Technical Set-Ups
at The Street - Thu Dec 18, 12:44PM CST
Wednesday's session featured some good moves and technical set-ups, particularly in biotech and technology.
RDUS: 50.37 (+0.63), OREX: 5.55 (+0.10), ACHN: 10.89 (-0.20), CLDX: 20.97 (+0.53), TASR: 26.96 (-0.42), DATA: 99.90 (+1.40)
Celldex Therapeutics Announces Appointment to Board of Directors
GlobeNewswire - Thu Dec 18, 7:10AM CST
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the appointment of Richard A. van den Broek to the Company's Board of Directors. Mr. van den Broek currently serves as a Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry. In addition, the Company announced that Timothy Shannon, MD has resigned from the Board due to demands on his time, including his roles as Chairman of the Board of Directors of Arvinas, Inc., a privately held biotechnology company and as a General Partner at Canaan Partners.
CLDX: 20.97 (+0.53)
